Given the way analysts feel about Quest Diagnostics right now, this huge implied volatility could mean there’s a trade developing.
The net effect has taken our Zacks Consensus Estimate for the current quarter from $2.25 per share to $2.26 in that period. Over the last 60 days, two analysts have increased the earnings estimates for the current quarter, while four have revised the estimates downward. Clearly, options traders are pricing in a big move for Quest Diagnostics shares, but what is the fundamental picture for the company? Currently, Quest Diagnostics is a Zacks Rank #3 (Hold) in the Medical - Outpatient and Home Healthcare industry that ranks in the Bottom 23% of our Zacks Industry Rank.
0 kommentar(er)
